Meiji Yasuda Asset Management Co Ltd. Has $11.35 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Meiji Yasuda Asset Management Co Ltd. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.5% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 20,522 shares of the medical research company’s stock after purchasing an additional 1,247 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Thermo Fisher Scientific were worth $11,349,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of TMO. Argent Trust Co increased its holdings in shares of Thermo Fisher Scientific by 2.5% during the 2nd quarter. Argent Trust Co now owns 22,552 shares of the medical research company’s stock worth $12,471,000 after acquiring an additional 551 shares during the last quarter. Meiji Yasuda Life Insurance Co boosted its position in Thermo Fisher Scientific by 1.2% during the second quarter. Meiji Yasuda Life Insurance Co now owns 15,582 shares of the medical research company’s stock worth $8,617,000 after purchasing an additional 186 shares during the period. Mercer Global Advisors Inc. ADV raised its position in shares of Thermo Fisher Scientific by 37.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 35,467 shares of the medical research company’s stock valued at $19,522,000 after purchasing an additional 9,656 shares during the period. Lingotto Investment Management LLP acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $2,956,000. Finally, Meridian Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 6.6% in the 2nd quarter. Meridian Wealth Partners LLC now owns 519 shares of the medical research company’s stock valued at $287,000 after buying an additional 32 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Lisa P. Britt sold 3,624 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the sale, the vice president now directly owns 13,699 shares in the company, valued at $8,397,760.98. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock worth $14,094,292 in the last 90 days. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Barclays dropped their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a report on Friday, June 28th. Royal Bank of Canada boosted their target price on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, Bank of America raised their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a report on Monday. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $632.89.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $610.26 on Wednesday. The business has a fifty day simple moving average of $595.23 and a 200 day simple moving average of $580.77. The company has a market cap of $232.95 billion, a P/E ratio of 39.14, a P/E/G ratio of 2.86 and a beta of 0.78. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The firm had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.15 earnings per share. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.